Evidence map›Paper›PMID 39282299›Full record

ArticlebioRxiv : the preprint server for biology2024

Mitochondrial Hyperactivity and Reactive Oxygen Species Drive Innate Immunity to the Yellow Fever Virus-17D Live-Attenuated Vaccine.

Samantha G Muccilli, Benjamin Schwarz, Forrest Jessop, Jeffrey G Shannon, Eric Bohrnsen, Byron Shue, Seon-Hui Hong, Thomas Hsu, Alison W Ashbrook, Joseph W Guarnieri and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Samantha G MuccilliInnate Immunity and Pathogenesis Section, Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT.
Benjamin SchwarzResearch Technologies Branch, NIAID, NIH, Hamilton, MT.
Forrest JessopImmunity to Pulmonary Pathogens Section, Laboratory of Bacteriology, NIAID, NIH, Hamilton, MT.
Jeffrey G ShannonInnate Immunity and Pathogenesis Section, Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT.
Eric BohrnsenResearch Technologies Branch, NIAID, NIH, Hamilton, MT.
Byron ShueInnate Immunity and Pathogenesis Section, Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT.
Seon-Hui HongLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.
Thomas HsuInnate Immunity and Pathogenesis Section, Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT.
Alison W AshbrookLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.
Joseph W GuarnieriCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA.
Justin LackIntegrated Data Sciences Section, Research Technologies Branch, NIAID, NIH.
Douglas C WallaceCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA.
Catharine M BosioImmunity to Pulmonary Pathogens Section, Laboratory of Bacteriology, NIAID, NIH, Hamilton, MT.
Margaret R MacDonaldLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.ORCID 0000-0003-3087-8079
Jonathan W YewdellCellular Biology Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD.
Sonja M BestInnate Immunity and Pathogenesis Section, Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT.ORCID 0000-0003-0206-297X

Funding

Unraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunityR01AI124690 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2016 to 2026
$8.3M
NIAID NIH HHS R01 AI124690
6 · The paper itself

Abstract

The yellow fever virus 17D (YFV-17D) live attenuated vaccine is considered one of the successful vaccines ever generated associated with high antiviral immunity, yet the signaling mechanisms that drive the response in infected cells are not understood. Here, we provide a molecular understanding of how metabolic stress and innate immune responses are linked to drive type I IFN expression in response to YFV-17D infection. Comparison of YFV-17D replication with its parental virus, YFV-Asibi, and a related dengue virus revealed that IFN expression requires RIG-I-like Receptor signaling through MAVS, as expected. However, YFV-17D uniquely induces mitochondrial respiration and major metabolic perturbations, including hyperactivation of electron transport to fuel ATP synthase. Mitochondrial hyperactivity generates reactive oxygen species (mROS) and peroxynitrite, blocking of which abrogated IFN expression in non-immune cells without reducing YFV-17D replication. Scavenging ROS in YFV-17D-infected human dendritic cells increased cell viability yet globally prevented expression of IFN signaling pathways. Thus, adaptation of YFV-17D for high growth uniquely imparts mitochondrial hyperactivity generating mROS and peroxynitrite as the critical messengers that convert a blunted IFN response into maximal activation of innate immunity essential for vaccine effectiveness.

Indexed as

electron transportlive-attenuated vaccinemitochondriareactive oxygen speciestype I interferonYellow fever virus

Identifiers

PMID39282299
PMCPMC11398391

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.